| AASLD

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

Read more about NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

Stephen A. Harrison, Stephen J. Rossi, Angelo H. Paredes, James F. Trotter, Mustafa R. Bashir, Cynthia D. Guy, Rajarshi Banerjee, Mark J. Jaros, Sandra Owers, Bryan A. Baxter, Lei Ling, Alex M. DePaoli – 25 February 2019 – NGM282, an engineered fibroblast growth factor 19 analogue, rapidly and significantly reduced liver fat content in a multicenter, randomized, double‐blind, placebo‐controlled study in patients with biopsy‐confirmed nonalcoholic steatohepatitis (NASH). However, it is unclear whether these changes would be accompanied by histological improvement.

Interleukin‐33/ST2‐Mediated Inflammation Plays a Critical Role in the Pathogenesis and Severity of Type I Autoimmune Hepatitis

Read more about Interleukin‐33/ST2‐Mediated Inflammation Plays a Critical Role in the Pathogenesis and Severity of Type I Autoimmune Hepatitis

Kazumichi Abe, Atsushi Takahashi, Masashi Fujita, Manabu Hayashi, Ken Okai, Yoshihiro Nozawa, Hiromasa Ohira – 25 February 2019 – Interleukin (IL)‐33 was recently described as a new member of the IL‐1 family; members of this family have proinflammatory activity. IL‐33 and its soluble receptor ST2 (sST2) have been implicated in the pathogenesis of autoimmune diseases. This study investigated serum IL‐33 and sST2 in type I autoimmune hepatitis (AIH) and the relationship of these molecules with clinical and pathologic parameters.

Reply

Read more about Reply

Maurizio Cesari – 25 February 2019

Letter to the Editor: Echocardiographic Predictors of a Worse Outcome in Patients With Liver Cirrhosis: What Should We Assess?

Read more about Letter to the Editor: Echocardiographic Predictors of a Worse Outcome in Patients With Liver Cirrhosis: What Should We Assess?

Roxana Cristina Rimbaş, Mihai Rimbaş, Dragoș Vinereanu – 25 February 2019

Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus–Associated Hepatocellular Carcinoma

Read more about Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus–Associated Hepatocellular Carcinoma

Yung‐Tsung Li, Hui‐Lin Wu, Jia‐Horng Kao, Huei‐Ru Cheng, Ming‐Chih Ho, Chih‐Chiang Wang, Pei‐Jer Chen, Ding‐Shinn Chen, Chun‐Jen Liu – 25 February 2019 – Overexpression of metastatic tumor antigen 1 (MTA1) was correlated with poor prognosis of hepatitis B virus (HBV)‐associated hepatocellular carcinoma (HBV‐HCC). The aim of this study was to examine the clinical significance of the expression of MTA1 and its exon 4‐excluded form (MTA1dE4), the most abundant spliced variant of MTA1, in patients receiving curative resection for HBV‐HCC.

Letter to the Editor: Defining Acute on Chronic Liver Failure: More Elusive Than Ever

Read more about Letter to the Editor: Defining Acute on Chronic Liver Failure: More Elusive Than Ever

Jasmohan S. Bajaj, Florence Wong, Patrick S. Kamath – 25 February 2019

Letter to the Editor: Tuberculosis and Antituberculosis Treatments Cannot Be Ignored When Evaluating Patients With Cirrhosis Who Are Coinfected With HIV or Not

Read more about Letter to the Editor: Tuberculosis and Antituberculosis Treatments Cannot Be Ignored When Evaluating Patients With Cirrhosis Who Are Coinfected With HIV or Not

RuiLing Wang, Peng Zhu – 25 February 2019

Letter to the Editor: Deliberations More Than a Cut‐off Hepatitis B Surface Antigen Value for Nucleos(t)ide Analogue Cessation

Read more about Letter to the Editor: Deliberations More Than a Cut‐off Hepatitis B Surface Antigen Value for Nucleos(t)ide Analogue Cessation

Wen‐Juei Jeng, Yao‐Chun Hsu, Tung‐Hung Su, Chien‐Hung Chen – 22 February 2019

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Read more about Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero, Laura M. Kulik, Claude B. Sirlin, Andrew X. Zhu, Richard S. Finn, Michael M. Abecassis, Lewis R. Roberts, Julie K. Heimbach – 21 February 2019

The Antiresection Activity of the X Protein Encoded by Hepatitis Virus B

Read more about The Antiresection Activity of the X Protein Encoded by Hepatitis Virus B

Laifeng Ren, Ming Zeng, Zizhi Tang, Mingyuan Li, Xiaojun Wang, Yang Xu, Yuding Weng, Xiaobo Wang, Huan Wang, Liandi Guo, Bing Zuo, Xin Wang, Si Wang, Jiangyan Lou, Yaxiong Tang, Dezhi Mu, Ning Zheng, Xianhui Wu, Junhong Han, Antony M. Carr, Penelope Jeggo, Cong Liu – 21 February 2019 – Chronic infection of hepatitis B virus (HBV) is associated with an increased incidence of hepatocellular carcinoma (HCC).

Subscribe to